190 related articles for article (PubMed ID: 31243601)
1. Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model.
Qelliny MR; Aly UF; Elgarhy OH; Khaled KA
AAPS PharmSciTech; 2019 Jun; 20(6):237. PubMed ID: 31243601
[TBL] [Abstract][Full Text] [Related]
2. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.
Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW
Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440
[TBL] [Abstract][Full Text] [Related]
3. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon.
Krishnamachari Y; Madan P; Lin S
Int J Pharm; 2007 Jun; 338(1-2):238-47. PubMed ID: 17368982
[TBL] [Abstract][Full Text] [Related]
4. Central composite design for the formulation and optimization of a multi-unit potential colonic drug delivery system of budesonide for ulcerative colitis.
Patel NV; Patel JK; Shah SH; Patel JN
Pharmazie; 2011 Feb; 66(2):124-9. PubMed ID: 21434575
[TBL] [Abstract][Full Text] [Related]
5. The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis.
Motawea A; Abd El Hady WE; Ahmed El-Emam G
Drug Deliv; 2022 Dec; 29(1):906-924. PubMed ID: 35297699
[TBL] [Abstract][Full Text] [Related]
6. Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis.
Crcarevska MS; Dodov MG; Petrusevska G; Gjorgoski I; Goracinova K
J Drug Target; 2009 Dec; 17(10):788-802. PubMed ID: 19938950
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of nanocapsules for colon-targeted drug delivery system.
Kshirsagar SJ; Bhalekar MR; Patel JN; Mohapatra SK; Shewale NS
Pharm Dev Technol; 2012; 17(5):607-13. PubMed ID: 21428704
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression.
Seoudi SS; Allam EA; El-Kamel AH; Elkafrawy H; El-Moslemany RM
Drug Deliv Transl Res; 2023 Nov; 13(11):2930-2947. PubMed ID: 37184747
[TBL] [Abstract][Full Text] [Related]
9. Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease.
Oshi MA; Naeem M; Bae J; Kim J; Lee J; Hasan N; Kim W; Im E; Jung Y; Yoo JW
Carbohydr Polym; 2018 Oct; 198():434-442. PubMed ID: 30093020
[TBL] [Abstract][Full Text] [Related]
10. Colon-Targeted Therapy of Tacrolimus (FK506) in the Treatment of Experimentally Induced Colitis.
Ali AS; Altayari AA; Khan LM; Alharthi SE; Ahmed OA; El-Shitany NA; Ali SS; Saadah OI
Pharmacology; 2020; 105(9-10):541-549. PubMed ID: 31940656
[TBL] [Abstract][Full Text] [Related]
11. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of budesonide-succinate-dextran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats.
Varshosaz J; Emami J; Fassihi A; Tavakoli N; Minaiyan M; Ahmadi F; Mahzouni P; Dorkoosh F
Int J Colorectal Dis; 2010 Oct; 25(10):1159-65. PubMed ID: 20669022
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis.
Zhou H; Qian H
Drug Des Devel Ther; 2018; 12():2601-2609. PubMed ID: 30174414
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis.
Ferri D; Costero AM; Gaviña P; Parra M; Merino V; Teruel AH; Sancenón F; Martínez-Máñez R
Int J Pharm; 2019 Apr; 561():93-101. PubMed ID: 30817986
[TBL] [Abstract][Full Text] [Related]
15. Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles.
Naeem M; Cao J; Choi M; Kim WS; Moon HR; Lee BL; Kim MS; Jung Y; Yoo JW
Int J Nanomedicine; 2015; 10():4565-80. PubMed ID: 26213469
[TBL] [Abstract][Full Text] [Related]
16. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging.
Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM
Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953
[TBL] [Abstract][Full Text] [Related]
17. pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model.
Makhlof A; Tozuka Y; Takeuchi H
Eur J Pharm Biopharm; 2009 May; 72(1):1-8. PubMed ID: 19348015
[TBL] [Abstract][Full Text] [Related]
18. Pulsatile systems for colon targeting of budesonide: in vitro and in vivo evaluation.
Yehia SA; Elshafeey AH; Elsayed I
Drug Deliv; 2011 Nov; 18(8):620-30. PubMed ID: 22111975
[TBL] [Abstract][Full Text] [Related]
19. Formulation and optimization of theophylline-loaded enteric-coated spanlastic nanovesicles for colon delivery; Ameliorate acetic acid-induced ulcerative colitis.
Barakat EH; Akl MA; Ibrahim MF; Mohamed Dawaba H; Afouna MI
Int J Pharm; 2023 Aug; 643():123253. PubMed ID: 37473974
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmaceutical study on colon targeted micro-particles of celecoxib: in-vitro-in-vivo evaluation.
Bazan L; Bendas ER; El Gazayerly ON; Badawy SS
Drug Deliv; 2016 Nov; 23(9):3339-3349. PubMed ID: 27086898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
